Fragmin® (dalteparin) – New indication
May 16, 2019 - The FDA announced the approval of Pfizer’s Fragmin (dalteparin), for the treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence of VTE in pediatric patients 1 month of age and older.
Download PDF
